✦ LIBER ✦

Treatment of “high risk” myelodysplastic syndromes (MDS) with idarubicin and cytosine arabinoside, supported by granulocyte-macrophage colony stimulating factor (GM-CSF)

✍ Scribed by T. Economopoulos; E. Papageorgiou; A. Parharidou; M. Constantinidou; J. Dervenoulas; N. Stathakis; S. Raptis

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of high risk myelodysplastic s

✍ Theofanis Economopoulos; Efstathios Papageorgiou; Nicholas Stathakis; Maria Cons 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 605 KB

Treatment of myelodysplastic syndromes w

✍ T. Economopoulos; E. Papageorgiou; N. Stathakis; N. Asprou; P. Karmas; J. Derven 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB

Fludarabine, cytosine arabinoside, granu

✍ Donald W. Milligan; Keith Wheatley; Alan K. Burnett 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Treatment of myelodysplastic syndromes w

✍ T. Economopoulos; E. Papageorgiou; N. Asprou; P. Karmas; J. Dervenoulas; H. Bour 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Effects of low doses of recombinant huma

✍ Elihu H. Estey; Razelle Kurzrock; Moshe Talpaz; Kenneth B. McCredie; Susan O'Bri 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 451 KB

Erythropoietin, with and without granulo

✍ K Miller 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 100 KB